Crovalimab-Akkz - Indications, Dosage, and Side Effects

Drug Overview:

Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder that arises not from inheritance but from acquired mutations, leading to the early destruction and impaired production of blood cells. This condition impacts red blood cells (erythrocytes) responsible for oxygen transport, white blood cells (leukocytes) that defend against infections, and platelets (thrombocytes) involved in blood clotting. In 2021, the FDA (Food and Drug Administration) approved Crovalimab-akkz for treating PNH in both adults and pediatric patients aged 13 and older, provided they weigh at least 40 kilograms (kg).

For Patients

What Are the Indications For Crovalimab-Akkz?

Crovalimab-akkz is indicated for treating patients with paroxysmal nocturnal hemoglobinuria (PNH). Specifically, it is approved for use in adult and pediatric patients who are 13 years or older and have a body weight of at least 40 kg. This medication helps manage the symptoms and complications associated with PNH, such as hemolysis (destruction of red blood cells), anemia, fatigue, and thrombosis (formation of blood clots).

What Is the Dosage of Crovalimab-Akkz?

The recommended dosage for the treatment is 0.5 mcg/kg (micrograms per kilogram)

What Are the Things to Inform the Doctor Before Taking the Drug?

• Infections.

• Liver problems.

• Kidney problems.

• Blood disorders.

• Autoimmune diseases.

• Pregnancy.

• Depression.

• Breastfeeding.

• Diabetes.

How Is Crovalimab-Akkz Administered?

Crovalimab-akkz is administered through two main methods:

• Intravenous (IV) Infusion:

  • This is typically used for the initial loading dose.

  • The medication is delivered directly into a vein through an IV line.

• Subcutaneous (SC) Injection:

  • This is used for maintenance doses after the initial IV infusion.

  • The medication is injected under the skin, usually weekly or biweekly.

What Are the Side Effects of Crovalimab-Akkz?

Common side effects of Crovalimab-akkz include:

• Injection site reactions (pain, redness, swelling).

• Headache.

• Fatigue.

• Fever.

• Upper respiratory tract infections.

• Diarrhea.

• Nausea.

Missed Dose:

Immediately inform the healthcare provider about the missed dose.

Overdose:

Watch for any signs of adverse reactions or side effects, such as severe allergic reactions, unusual bruising or bleeding, or any other concerning symptoms.

Storage:

Once Crovalimab-akkz is drawn into the syringe from the vial, it should be injected immediately since it lacks any antimicrobial preservatives. If it cannot be used immediately, the capped syringe can be kept in the refrigerator between two degrees Celsius and eight degrees Celsius (36 degrees Fahrenheit to 46 degrees Fahrenheit) for up to 64 hours, shielded from light.

For Doctors

Indication:

Crovalimab-akkz is recommended for treating paroxysmal nocturnal hemoglobinuria (PNH) in patients aged 13 years and older who weigh at least 40 kg.

Dose:

The prescribed dosage regimen includes an initial loading dose given via intravenous (IV) infusion on Day one, followed by four more weekly loading doses administered through subcutaneous (SUBQ) injection on Days 2, 8, 15, and 22. The maintenance dose begins on Day 29 and continues with subcutaneous injections every four weeks after that.

Dosing Considerations:

• Variations in the dosing schedule by up to 2 days from the scheduled administration day are permissible, except for Day one and Day two.

• In such cases, the next dose should be administered per the usual schedule.

• Adjustment of the maintenance dose is necessary if the patient's body weight consistently changes to exceed or fall below 100 kg during treatment.

What Are the Pharmacological Aspects of Crovalimab-Akkz?

Mechanism Of Action:

Crovalimab-Akkz, also known simply as Crovalimab, is a monoclonal antibody designed to intervene in the complement cascade, a crucial part of the immune system involved in inflammation and immune defense. Its mechanism of action centers on specifically targeting and binding to complement component C5 (a protein in the complement system, part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells).

• Targeting C5: Crovalimab selectively binds to complement C5, a protein central to the complement system. Complement activation plays a pivotal role in innate and adaptive immunity, contributing to the body's defense against pathogens and the clearance of damaged cells.

• Inhibition of C5 Cleavage: Upon binding to C5, Crovalimab effectively prevents the enzyme C5 convertase from cleaving it into C5a and C5b. This step is critical because C5a is a potent pro-inflammatory molecule.

• Blockade of C5a and MAC Formation: By halting C5 cleavage, Crovalimab inhibits the generation of C5a and prevents the assembly of the MAC. C5a is known to induce inflammation by activating immune cells and promoting the release of cytokines. The MAC, when formed, inserts into cell membranes, leading to cell destruction through osmotic lysis.

• Therapeutic Impact: Crovalimab's inhibition of C5 can significantly reduce this pathological process. By blocking C5, Crovalimab helps mitigate hemolysis and the associated complications, thereby improving patients' clinical outcomes and quality of life.

• Clinical Applications: Crovalimab's ability to modulate the complement system makes it a promising therapeutic option for PNH and other complement-mediated disorders where excessive complement activation contributes to disease pathology. Its targeted mechanism offers a specific intervention to restore complement regulation and alleviate symptoms associated with dysregulated complement activation.

Pharmacokinetics:

• Absorption: Crovalimab-Akkz is administered exclusively via intravenous (IV) infusion. This route ensures rapid and complete bioavailability, as the drug is directly introduced into the bloodstream. The IV administration allows Crovalimab to achieve therapeutic concentrations quickly, bypassing the absorption barriers encountered with oral medications. This immediate availability in systemic circulation facilitates prompt interaction with its target, complement component C5, thereby initiating its pharmacological action without delay.

• Distribution: Upon entering systemic circulation, Crovalimab is primarily distributed within the vascular compartment due to its large molecular size (~150 kDa) and specific binding to complement C5. The distribution into extravascular tissues is limited, as the antibody molecule remains confined within the blood vessels. Crovalimab does not penetrate significantly across the blood-brain barrier, which restricts its exposure to the central nervous system. The distribution profile ensures that therapeutic concentrations are maintained where complement-mediated activity occurs, such as in the peripheral blood and tissues affected by complement dysregulation.

• Metabolism: Being a monoclonal antibody, Crovalimab undergoes metabolic degradation akin to endogenous immunoglobulin G (IgG) antibodies. Metabolism primarily involves proteolytic cleavage into smaller peptides and amino acids within the reticuloendothelial system (RES), particularly in the liver. This degradation process is part of the body's natural turnover of antibody molecules. The metabolic fate of Crovalimab aligns with typical pathways observed for therapeutic antibodies, ensuring efficient clearance of the drug over time.

• Elimination: The elimination of Crovalimab is predominantly governed by its clearance rate, which involves nonspecific proteolytic degradation and renal excretion. The drug's elimination half-life reflects the time required for its plasma concentration to decline by half, indicating the duration of systemic exposure. Clearance occurs through metabolic breakdown within the RES and subsequent elimination of intact or partially degraded drug components via the kidneys. While renal excretion contributes to overall clearance, Crovalimab's large molecular size and specific binding properties to C5 minimize extensive filtration through the renal glomeruli.

Pharmacodynamics:

• Biomarker Assessment:

  • Monitoring levels of hemoglobin, lactate dehydrogenase (LDH), and reticulocytes can provide insights into the effectiveness of Crovalimab in reducing hemolysis.

  • Complement activity assays may be used to measure the inhibition of C5 and ensure therapeutic levels are achieved.

• Adverse Effects: Common side effects may include infusion-related reactions, infections, and headaches. Given the role of the complement system in immune defense, monitoring for infections is crucial.

Clinical Studies And Efficacy:

• An active-controlled, open-label, non-inferiority study evaluating the efficacy of Crovalimab-akkz in patients with paroxysmal nocturnal hemoglobinuria (PNH).

• The study enrolled 204 patients with PNH. These patients had a body weight of at least 40 kg.

• Patients weighing 40 kg and 100 kg received a single intravenous (IV) loading dose of 1,000 mg.

• Patients weighing over 100 kg received a single IV loading dose of 1,500 mg. Maintenance subcutaneous doses were administered every four weeks. Patients weighing between 40 kg and 100 kg received 680 mg, while patients weighing over 100 kg received 1,020 mg.

• Crovalimab-akkz demonstrated effectiveness in controlling hemolysis, as a significant proportion of patients maintained LDH levels within the target range.

• Patients treated with Crovalimab-akkz showed significant hemoglobin stabilization, indicating the drug's effectiveness in maintaining stable hemoglobin levels.

What Are the Contraindications of Crovalimab-Akkz?

• Initiation of treatment during an active and unresolved serious Neisseria meningitidis infection.

• Severe hypersensitivity to Crovalimab or any of its components.

Warnings and Precautions:

Serious Meningococcal Infection:

• Increased Susceptibility to Infections: Crovalimab-akkz , as a complement inhibitor, makes patients more prone to serious, life-threatening, or fatal infections caused by meningococcal bacteria (meningococcemia and meningitis) affecting any serogroup, including non-groupable-strains. Both vaccinated and unvaccinated patients have experienced life-threatening and fatal meningococcal infections while being treated with complement inhibitors.

• Contraindications: Crovalimab-akkz should not be started in patients with an unresolved serious Neisseria meningitidis infection.

• Vaccination Requirements: Complete or update vaccinations for meningococcal serogroups, two weeks before administering the first Crovalimab-akkz , following the Advisory Committee on Immunization Practices (ACIP) guidelines for patients on complement inhibitors. Patients should be revaccinated according to ACIP recommendations, considering the duration of Crovalimab-akkz therapy.

• Urgent Treatment Protocol: If Crovalimab-akkz treatment must be initiated urgently in a patient not up to date with meningococcal vaccines per ACIP guidelines, administer antibacterial prophylaxis and the meningococcal vaccines as soon as possible. Optimal duration and regimens for antibacterial prophylaxis have not been studied in patients, whether vaccinated or unvaccinated, receiving complement inhibitors like Crovalimab-akkz . The benefits and risks of Crovalimab-akkz treatment and antibacterial prophylaxis should be weighed against the known risks of serious infections caused by N. meningitidis.

• Vaccination Limitations: Vaccination does not eliminate the risk of meningococcal infections, even if antibodies are developed post-vaccination.

• Monitoring and Treatment: Inform patients about these signs and symptoms and instruct them to seek immediate medical care if they occur. Promptly treat any known infections, as meningococcal infections can become fatal if not treated early. Consider interrupting Crovalimab-akkz treatment in patients undergoing treatment for serious meningococcal infection.

Crovalimab-akkz REMS:

Program Requirements: Due to the risk of serious meningococcal infections, Crovalimab-akkz is only available through the Crovalimab-akkz REMS program.

Requirements include:

• Prescribers must enroll in the REMS program.

• Prescribers must counsel patients about the risk of serious meningococcal infection.

• Prescribers must provide patients with educational materials from the REMS.

• Prescribers must assess and update the patient’s meningococcal vaccination status and vaccinate if needed per ACIP recommendations two weeks before the first dose of Crovalimab-akkz .

• If urgent treatment is necessary and the patient is not up to date with meningococcal vaccines, provide a prescription for antibacterial prophylaxis.

• Healthcare settings and pharmacies dispensing Crovalimab-akkz must be certified in the REMS program and verify prescriber certification.

• Patients must be counseled on needing meningococcal vaccines, taking antibiotics as directed, and recognizing signs and symptoms of meningococcal infection.

• Patients must always carry a Patient Safety Card during and for 11 months following treatment with Crovalimab-akkz .

Type III Hypersensitivity Reactions

• Risk of Hypersensitivity: Patients switching from another C5 inhibitor (e.g., Eculizumab or Ravulizumab) to Crovalimab-akkz or vice versa are at risk for serious Type III hypersensitivity reactions due to drug-target-drug complexes (DTDCs) formation, as these inhibitors bind different C5 epitopes.

• Clinical Trial Data: In trials, 19 % of patients switching from Eculizumab or Ravulizumab to Crovalimab-akkz experienced Type III hypersensitivity reactions. Of these, 10 % had not fully recovered by the last follow-up. Similarly, 25 % of patients switching from Crovalimab-akkz to another C5 inhibitor experienced such reactions, including a case of Grade three axonal neuropathy.

• Symptoms: Common symptoms included arthralgia, rash, fever, myalgia, headache, fatigue, petechiae, and abdominal pain. Serious reactions, causing hospitalization, included fever and arthralgia.

• Risk Management: Healthcare providers should weigh the benefits and risks of switching C5 inhibitors. Avoid starting Crovalimab-akkz within 5.5 half-lives of the last C5 inhibitor dose, and vice versa. Monitor patients for the first 30 days of new therapy for symptoms of hypersensitivity reactions. Treat mild or moderate reactions symptomatically; initiate corticosteroid therapy as clinically indicated for severe reactions.

Other Infections

• Increased Susceptibility: Due to its action, AZ may increase the risk of infections such as Neisseria, Streptococcus pneumoniae, Haemophilus influenzae, and, to a lesser extent, Neisseria gonorrhoeae. Children on Crovalimab-akkz may have a higher risk of serious infections from Streptococcus pneumoniae and Haemophilus influenzae type b (Hib).

• Vaccinations: Vaccinate patients against Streptococcus pneumoniae and Hib according to ACIP guidelines. If Crovalimab-akkz is administered to patients with active systemic infections, monitor closely for signs of worsening infection and consider discontinuing Crovalimab-akkz if the infection worsens.

Infusion- and Injection-Related Reactions

• Possible Reactions: Crovalimab-akkz administration may cause infusion-related or injection-related reactions, including hypersensitivity reactions (anaphylaxis), injection site pain, erythema, headache, or myalgia. In clinical trials, one serious infusion-related reaction was resolved four days after stopping the infusion.

• Management: Instruct patients to seek immediate medical attention if serious hypersensitivity reactions occur. Discontinue Crovalimab-akkz immediately and treat it appropriately. Crovalimab-akkz is contraindicated in patients with known serious hypersensitivity to Crovalimab or any excipients.

Monitoring After Discontinuation

• Post-Discontinuation Monitoring: If Crovalimab-akkz is discontinued without switching to another PNH treatment, closely monitor patients for at least 20 weeks for serious hemolysis signs, including elevated LDH, sudden hemoglobin drop, or symptoms like fatigue, hemoglobinuria, abdominal pain, dyspnea, major vascular events (thrombosis), dysphagia, erectile dysfunction, or renal impairment.

• Treatment Resumption: If signs of hemolysis occur, consider restarting Crovalimab-akkz or initiating another PNH treatment.

Specific Considerations

• Pregnancy: The available data on Crovalimab-akkz use in pregnant women are inadequate to assess the risk of major birth defects associated with the drug. Since human IgG antibodies, which can cross the placenta, increase in transport as pregnancy progresses and peak during the third trimester, Crovalimab-akkz might be transmitted from mother to fetus. There are risks to both mother and fetus linked to untreated PNH during pregnancy.

• Lactation: There is no data on the presence of Crovalimab-akkz in human or animal milk, its effects on a breastfed child, or its impact on milk production. Due to serious adverse reactions in a breastfed child, it is advised that patients do not breastfeed during treatment with Crovalimab-akkz and for nine months after the last dose.

• Pediatric Use: The safety and effectiveness of Crovalimab-akkz for treating PNH have been established in pediatric patients aged 13 years and older who weigh at least 40 kg. The safety and efficacy of Crovalimab-akkz have not been established in pediatric patients younger than 13 years or those weighing less than 40 kg.

• Geriatric Use: Clinical studies of Crovalimab-akkz did not include enough subjects for old age assessment. Generally, dose selection should be cautious, considering the higher frequency of the presence of concomitant diseases.